In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Wright Medical Back on Track?

Executive Summary

Wright Medical hasn’t enjoyed the smoothest ride over the past 15 years, a stretch that included a spin-out, debt problems, and a buyout, as well as an IPO. All the while, though, the company has proven to be an innovator in the large joints industries and now—under new CEO Gary Henley—it is establishing itself as a force in the extremities and biomaterials markets.

You may also be interested in...



Can MicroPort Master Orthopedics?

China’s MicroPort Scientific paid $290 million in cash for Wright Medical’s hip and knee business, which has a pipeline of products – including FDA approved implants – ready for sale in China’s growing orthopedics market. The acquisition pits MicroPort against multinationals that previously held an edge selling implants to Chinese patients and doctors who seem to favor devices that carry approval from the US FDA.

New Technologies Drive Growth In Orthopedic Extremities Market

While the mature hips, knees, and spine segments of the orthopedics industry are growing by low single-digit rates, some sectors of the extremity industry are growing by 13% to 14%. START-UP profiles three companies in different sectors of extremities: Conventus Orthopaedics, in the hand and wrist market, Nextremity Solutions, working on devices for the forefoot, and Cartiva Medical, with a cartilage platform and an initial focus on the great toe.

Ascension Orthopedics' Fate May Rest on the Shoulder

After more than a decade of crafting small bone orthopedic implants from its innovative PyroCarbon biomaterial, Ascension is hoping to reach its full potential by obtaining regulatory approval for a line of carbon shoulder replacement systems that might change the way the joint is treated.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PL000723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel